Aspire-Lakewood Holdings, Inc.
Moat Score — Aspire-Lakewood Holdings, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Holds patent-pending sublingual delivery formulations (provisional applications filed 2023 and 2024) and a favorable FDA pre-IND response for its lead aspirin program, but the underlying active ingredients (aspirin, semaglutide, melatonin, vitamins) are off-patent commodities, so protection rests on narrow formulation/delivery claims rather than composition-of-matter patents, and no product has yet received FDA approval. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | The company owns no manufacturing capacity, relies entirely on third-party contract manufacturers (Glatt, Microsize, Supranaturals), and has itself disclosed that its primary manufacturer's capacity may be insufficient for planned needs, giving it no discernible cost advantage over incumbents. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Pre-revenue in any material sense (net revenue of $1,941 in Q3 2025 from a caffeine supplement); its lead aspirin program would compete against cheap, decades-old OTC analgesics (Bayer, Advil, Tylenol), leaving no demonstrated ability to set or sustain premium pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A drug-delivery reformulation business with no platform, marketplace, or user-base dynamics; product value does not increase as more patients or prescribers adopt it, so no network effect exists. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If approved, hospital/EMS adoption of a specific acute-care protocol (sublingual aspirin for suspected MI) could create modest institutional switching costs once embedded, but today there is no approved product, no prescriber base, and no evidence of entrenched usage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Operates in large, highly competitive markets (OTC analgesics, GLP-1 diabetes/weight-management therapies, supplements) with no evidence of a naturally limited market that deters entry; numerous better-capitalized competitors can pursue similar reformulation or alternative fast-onset strategies. |